RANK is a poor prognosis marker and a therapeutic target in ER‐negative postmenopausal breast cancer

RANK is a poor prognosis marker and a therapeutic target in ER‐negative postmenopausal breast cancer

Abstract Despite strong preclinical data, the therapeutic benefit of the RANKL inhibitor, denosumab, in breast cancer patients, beyond the bone, is unclear. Aiming to select patients who may benefit from denosumab, we hereby analyzed RANK and RANKL protein expression in more than 2,000 breast tumors...

Full description

Bibliographic Details
Main Authors: Marina Ciscar, Eva M Trinidad, Gema Perez‐Chacon, Mansour Alsaleem, Maria Jimenez, Maria J Jimenez‐Santos, Hector Perez‐Montoyo, Adrian Sanz‐Moreno, Andrea Vethencourt, Michael Toss, Anna Petit, Maria T Soler‐Monso, Victor Lopez, Jorge Gomez‐Miragaya, Clara Gomez‐Aleza, Lacey E Dobrolecki, Michael T Lewis, Alejandra Bruna, Silvana Mouron, Miguel Quintela‐Fandino, Fatima Al‐Shahrour, Antonio Martinez‐Aranda, Angels Sierra, Andrew R Green, Emad Rakha, Eva Gonzalez‐Suarez
Format: Article
Language:English
Published: Springer Nature 2023-04-01
Series:EMBO Molecular Medicine
Subjects:
breast cancer patient‐derived xenografts
ER negative breast cancer
menopause
pharmacological RANKL inhibitors
RANK‐RANKL
Online Access:https://doi.org/10.15252/emmm.202216715

Internet

https://doi.org/10.15252/emmm.202216715

Similar Items